Total Body Irradiation for Acute Leukemia
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Total Body Irradiation for Acute Leukemia?
Research shows that patients with acute leukemia who received total body irradiation (TBI) as part of their treatment had better two-year survival rates (77%) compared to those who did not receive TBI (51%). Additionally, the relapse rate was lower in the TBI group (16%) compared to the non-TBI group (37%).12345
Is total body irradiation safe for humans?
Total body irradiation (TBI) has been used in treating acute leukemia, and studies have looked at both early and late side effects. Some patients may experience complications like interstitial pneumonitis (lung inflammation), but TBI can also help reduce the risk of leukemia returning. Overall, TBI is considered a part of treatment regimens, with safety data showing both risks and benefits.34567
How is total body irradiation treatment different for acute leukemia?
Total body irradiation (TBI) is unique because it involves exposing the entire body to radiation to prepare patients for bone marrow transplantation, which helps reduce the risk of leukemia returning. Unlike other treatments, TBI is often used in combination with chemotherapy to improve survival rates and reduce relapse in patients with acute leukemia.458910
What is the purpose of this trial?
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to compare the rates of graft-versus-host disease-free and relapse-free survival (GRFS) between patients in the two cohorts.
Research Team
Jonathan Webster
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria
This trial is for patients of any age with acute leukemia (AML, ALL, or mixed/ambiguous lineage) who are undergoing their first allogeneic blood or marrow transplant. Eligible participants include those with a history of myeloproliferative neoplasm (MPN), myelodysplastic syndrome/neoplasm (MDS), and/or MDS/MPN-overlap if they've had specific prior treatments.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning
Participants receive reduced-intensity conditioning with chemotherapy and total body irradiation (TBI) before stem cell transplantation
Transplantation
Stem cell transplantation is performed after conditioning regimen
Post-Transplantation Treatment
Participants receive post-transplantation cyclophosphamide and other medications to prevent graft-versus-host disease
Follow-up
Participants are monitored for safety, engraftment, and effectiveness of the transplant
Treatment Details
Interventions
- Total Body Irradiation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor